Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397301 | 0.87 | MLNR (0.47) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6500680 | 0.84 | CTSD (0.40) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL9123183 | 0.82 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5389293 | 0.82 | PSEN1 (0.39) | SPPL2AMLNRABCB11CTSDPSEN1 | |
| SCHEMBL7670354 | 0.80 | SPPL2A (0.37) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL8564599 | 0.79 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9121380 | 0.78 | SPPL2A (0.48) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL8260637 | 0.77 | CTSD (0.40) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL8842365 | 0.77 | SPPL2A (0.49) | SPPL2A | |
| SCHEMBL9119249 | 0.77 | SPPL2A (0.49) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-01 | — | — | US | claimed |
| US-6515024-B2 | For therapy of retroviral infection, e.g., an HIV infection | G. D. SEARLE & CO. | 2003-02-04 | — | — | US | claimed |
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-12-26 | — | — | US | claimed |
| US-7199158-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-01-26 | — | — | US | disclosed |
| US-6951886-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-01 | — | — | US | disclosed |
| US-6515024-B2 | For therapy of retroviral infection, e.g., an HIV infection | G. D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-12-26 | — | — | US | disclosed |
| US-6337398-B1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | HAT1, UBXN4, PRSS1 | SPPL2A 922/4885MLNR 2114/4885ABCB11 3595/4885 |
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | SUMO1, CHUK, SENP1 | SPPL2A 212/4885MLNR 3166/4885ABCB11 3973/4885 |
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | SUMO1, CHUK, SENP1 | SPPL2A 212/4885MLNR 3166/4885ABCB11 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.